Editor's note

This ExpertREACT article was originally published on 21 May 2009. Epidemiological data and demand estimates described reflect the state of knowledge at that date.

H1N1 at Level 5: modelling demand

As of 20 May 2009, the novel triple reassortant H1N1 influenza A virus - previously referred to as "swine flu" - had caused over 10,000 laboratory-confirmed cases of infection with 80 deaths across 41 countries, with over half of cases identified in the continental United States. The WHO pandemic alert had been raised to Level 5 - one level below a full pandemic declaration - widely expected to reach Level 6 if community-level sustained transmission was confirmed in another world region. Japan was already experiencing spread of the virus with school closures in Kobe. As of the WHO's 19 May update, it was considered premature to recommend immediate commercial-scale H1N1 vaccine production - a stance VacZine Analytics anticipated would change imminently.

VacZine Analytics' demand modelling for a potential US H1N1 vaccination programme estimated that US authorities would need to spend in excess of $1bn procuring a new vaccine - a figure that would depend heavily on the dose schedule required per person (one or two doses), the pricing government could negotiate, and the size of priority groups. Early California hospitalisation case data - median patient age 27.5 years, with a large proportion having underlying conditions including chronic lung disease - suggested H1N1 had particular impact on younger and medically vulnerable populations rather than the elderly cohort most targeted by seasonal influenza programmes.

Estimated US H1N1 vaccine procurement cost
>$1bn
VacZine Analytics minimum estimate for US government H1N1 vaccine procurement based on initial demand modelling, as of May 2009

Manufacturing constraints: the critical bottleneck

The immediate constraint on H1N1 vaccine supply was manufacturing capacity. Global influenza vaccine manufacturing was dominated by egg-based processes and tightly scheduled around seasonal vaccine production - any large-scale pandemic vaccine programme would compete directly with seasonal flu manufacturing. Cell-based and recombinant technologies - while faster and more flexible in theory - remained in early deployment with limited global capacity. VacZine Analytics argued that the H1N1 experience should be the catalyst for accelerating investment in next-generation influenza vaccine manufacturing technologies to ensure pandemic preparedness was genuinely achievable within an acceptable timeframe.